Phase 2 Completed N=170 Randomized Single-blind Treatment

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

Major Depressive Disorder

Source: ClinicalTrials.gov NCT00742573 ↗

Enrolled (actual)

170

Serious AEs

0.0%

Results posted

Mar 2020

Primary outcomePrimary: Mean Time of Retention — 27.08; 25.84 weeks

Summary

This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Time of Retention	27.08; 25.84	—
PRIMARY Hamilton Depression Scale (HAMD-17)	23.89; 22.42	—

Eligibility Criteria

Inclusion Criteria

Hispanic males and females
DSM-IV criteria for non-psychotic major depressive disorder (MDD) of at least moderate severity (HAM-D-17> 18)
18- 79
Patients with stable dosage of Benzodiazepines to treat anxiety disorders

Exclusion Criteria

At risk of attempting suicide
Unstable medical illness
History of bipolar disorder, schizophrenia, or other psychotic disorder
Pregnant or lactating
Alcohol or substance use disorder that requires acute detoxification

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00742573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.